Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
July 2, 2015
Revance Therapeutics Announces Change in Role of Jacob Waugh, M.D.
June 3, 2015
Revance Therapeutics to Initiate Two Key Trials for RT001, Its Topical Botulinum Toxin Type A Investigational Drug Product Candidate
May 21, 2015
Revance to Participate in Upcoming Investor Conferences
May 13, 2015
Revance Therapeutics Releases First Quarter 2015 Financial Results
April 29, 2015
Revance Therapeutics to Release First Quarter 2015 Financial Results Wednesday, May 13, 2015
March 2, 2015
Revance Therapeutics Releases Fourth Quarter and Full Year 2014 Financial Results and Reiterates 2015 Outlook
February 26, 2015
Revance Appoints Dr. Philip Vickers to Its Board of Directors
February 17, 2015
Revance Therapeutics, Inc. Announces Participation in Cowen 35th Annual Health Care Conference
February 12, 2015
Revance Therapeutics to Release Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on Monday, March 2, 2015
January 12, 2015
Revance Therapeutics Defines Clinical Program Milestones and Provides Financial Guidance for 2015
Displaying 251 - 260 of 298